Prevalence and clinical implications of persistent or exertional cardiopulmonary symptoms following SARS-CoV-2 infection in 3597 collegiate athletes: a study from the Outcomes Registry for Cardiac Conditions in Athletes (ORCCA)

Bradley J Petek, Nathaniel Moulson, Aaron L Baggish, Stephanie A Kliethermes, Manesh R Patel, Timothy W Churchill, Kimberly G Harmon, Jonathan A Drezner

ABSTRACT

Objective To assess the prevalence and clinical implications of persistent or exertional cardiopulmonary symptoms in young competitive athletes following SARS-CoV-2 infection.

Methods This observational cohort study from the Outcomes Registry for Cardiac Conditions in Athletes included 3597 US collegiate athletes after SARS-CoV-2 infection. Clinical characteristics, advanced diagnostic testing and SARS-CoV-2-associated sequelae were compared between athletes with persistent symptoms >3 weeks, exertional symptoms on return to exercise and those without persistent or exertional symptoms.

Results Among 3597 athletes (mean age 20 years, SD 1 year, 34% female), data on persistent and exertional symptoms were reported in 3529 and 3393 athletes, respectively. Persistent symptoms >3 weeks were present in 44/3529 (1.2%) athletes with 2/3529 (0.06%) reporting symptoms >12 weeks. Exertional cardiopulmonary symptoms were present in 137/3393 (4.0%) athletes. Clinical evaluation and diagnostic testing led to the diagnosis of SARS-CoV-2-associated sequelae in 12/137 (8.8%) athletes with exertional symptoms (five cardiac involvement, two pneumonia, two inappropriate sinus tachycardia, two postural orthostatic tachycardia syndrome and one pleural effusion). No SARS-CoV-2-associated sequelae were identified in athletes with isolated persistent symptoms. Of athletes with chest pain on return to exercise who underwent cardiac MRI (CMR), 5/24 (20.8%) had probable or definite cardiac involvement. In contrast, no athlete with exertional symptoms without chest pain who underwent CMR (0/20) was diagnosed with probable or definite SARS-CoV-2 cardiac involvement.

Conclusion Collegiate athletes with SARS-CoV-2 infection have a low prevalence of persistent or exertional symptoms on return to exercise. Exertional cardiopulmonary symptoms, specifically chest pain, warrant a comprehensive evaluation.

INTRODUCTION

SARS-CoV-2 infection may result in persistent symptoms or prolonged recovery in hospitalised patients suffering severe disease and in non-hospitalised patients with mild to moderate illness. Symptoms lasting beyond 3–4 weeks are considered prolonged, and those lasting greater than 12 weeks have been termed ‘chronic COVID-19’ or ‘postacute COVID-19 syndrome’ (PACS). PACS is a diagnosis of exclusion, and other possible disease sequelae, including inflammatory heart disease or pulmonary embolism (PE), require consideration in the appropriate clinical context.

The proportion of young competitive athletes with severe SARS-CoV-2 infection, defined by a requirement for hospitalisation, is low (0.2%). The prevalence of prolonged symptoms in adult non-athletes that do not require hospitalisation is reported to be up to 47%. Prolonged symptoms in this population are associated with the presence of ≥1 comorbidity and ≥6 separate symptoms during the acute illness. To date, no studies exist on the prevalence of prolonged symptoms in young competitive athletes. Additionally, a unique and potentially concerning clinical scenario in the athlete population is the presence of exertional symptoms on return to exercise which could reflect dangerous, previously undiagnosed underlying cardiopulmonary pathology. While the risk of SARS-CoV-2 cardiac involvement in young and otherwise healthy athletes appears relatively rare in large cohort studies (0.5%–3.0%), the presence of cardiopulmonary symptoms, including chest pain and dyspnoea, was identified as an independent predictor of SARS-CoV-2 cardiac involvement.

The Outcomes Registry for Cardiac Conditions in Athletes (‘ORCCA Registry’) was designed to collect data documenting symptoms, diagnostic testing, cardiac and non-cardiac diagnoses, and attendant clinical outcomes among US collegiate athletes returning to organised sports during the SARS-CoV-2 pandemic.

METHODS

This prospective observational cohort study included National Collegiate Athletic Association institutions who implemented SARS-CoV-2 infection testing and submitted data to the ORCCA Registry. The primary aim of this study was to describe the prevalence and clinical implications of persistent or exertional symptoms on return to
exercise in athletes following SARS-CoV-2 infection. A detailed description of the ORCCA Registry can be found elsewhere. For the current study, deidentified data were collected from participating institutions from 1 September 2020 to 1 May 2021, inclusive of all athletes with prior SARS-CoV-2 infection. Inclusion criteria for this study were: (1) athletes with confirmed SARS-CoV-2 infection by laboratory testing (PCR, antigen or antibody) and (2) reported initial symptom duration or presence of exertional symptoms on return to exercise. SARS-CoV-2 testing was performed to screen asymptomatic athletes prior to participation, for surveillance in asymptomatic athletes, and in symptomatic athletes per the discretion of participating institutions. Each participating institution submitted data via a standardised data capture tool and deidentified original clinical reports of the cardiovascular testing performed.

Definitions
Persistent symptoms were defined as symptoms lasting >3 weeks from initial symptom onset. Exertional cardiopulmonary symptoms were defined as any symptom of chest pain, shortness of breath (SOB), exercise intolerance/fatigue, palpitations/ tachycardia or presyncope/syncope on return to exercise. Initial symptom severity was also prespecified into the following categories: (1) asymptomatic, (2) mild, (3) moderate and (4) cardiopulmonary. Mild symptoms were defined as cough, fatigue, gastrointestinal symptoms (nausea, vomiting and/or diarrhoea), headache, anosmia, ageusia, rhinorrhea, sore throat or nasopharyngeal congestion. Moderate symptoms were defined as the presence of fever, chills, myalgias or COVID-19 toes/fingers. Cardiopulmonary symptoms were defined as chest pain, SOB, palpitations or exercise intolerance. If an athlete had symptoms in multiple categories, they were assigned the most severe category based on their symptoms.

‘Triad’ testing refers to the combination of 12-lead ECG, troponin and transthoracic echocardiogram (TTE). Abnormal ECGs and TTEs were adjudicated as possibly related to SARS-CoV-2 infection using prespecified definitions (online supplemental table 1). A troponin measurement was considered abnormal when >99% upper limits of normal per the local laboratory commercial assay standards. Advanced diagnostic testing was defined as any of the following (beyond triad testing): cardiac MRI (CMR), cardiac stress testing, cardiopulmonary exercise testing (CPET), chest X-ray, coronary CT angiography, CT-PE protocol, ambulatory Holter/event monitoring or pulmonary function testing.

Abnormal diagnostic testing was defined as any test which led to a diagnosis of SARS-CoV-2-associated sequelae per the clinical assessment performed by participating institutions. SARS-CoV-2-associated sequelae were defined as any new cardiac or pulmonary diagnosis reported by the local institution based on diagnostic testing or clinical evaluation.

Definitions for cardiac involvement from SARS-CoV-2 infection were adapted from the Updated Lake Louise Imaging criteria. Define myocardial involvement was defined as: (1) CMR T1 abnormality or late gadolinium enhancement (LGE)+T2 abnormality or (2) CMR T2 abnormality +one or more supportive findings (left ventricular ejection fraction (LVEF)<45%, small or greater pericardial effusion, pericardial enhancement or troponin >99% upper limit of normal). Probable myocardial involvement was defined as: (1) CMR T1 abnormality or presence of LGE+one or more supportive finding (same as definite myocardial involvement). Possible myocardial involvement was defined as: (1) isolated CMR T1 abnormality or presence of LGE. SARS-CoV-2 pericardial involvement was defined as a small or greater pericardial effusion or pericardial enhancement on CMR. Any athlete meeting criteria for myocardial involvement of SARS-CoV-2 infection who also had pericardial involvement was labelled as definite, probable or possible myopericardial involvement based on the definitions for myocardial involvement. For the analysis in this study, only definite or probable cardiac involvement were included as SARS-CoV-2-associated sequelae. Possible cardiac involvement was not considered a relevant sequela given the uncertain relationship of these findings to SARS-CoV-2 infection and unclear prognostic significance.

Statistical analysis
Standard descriptive statistics were used to describe the data. Continuous variables are presented as means and SD or medians and IQR as appropriate, and Student’s t-test was used for between group comparisons. Categorical variables are presented as n (%) and compared using the χ² test or Fischer’s exact test. Statistical analyses were performed using R: A Language and Environment for Statistical Computing (R Core Team, Vienna, Austria, year 2020, https://www.R-project.org/).

Patient and public involvement
Patients and the public were not involved in the design, conduct or analysis of this study.

RESULTS
Among 3644 athletes with SARS-CoV-2 infection submitted to the ORCCA Registry, 3597 (99%) met study inclusion criteria (figure 1). Baseline characteristics stratified by the presence of persistent symptoms and presence of exertional cardiopulmonary symptoms on return to exercise are presented in table 1. The total cohort is composed of athletes from 44 colleges/universities, including athletes representing 26 distinct sporting disciplines.

Persistent symptoms cohort
Symptom duration was reported in 3529/3597 (98.1%) of athletes. Persistent symptoms >3 weeks from symptom onset...
Table 1  Patient characteristics based on the prevalence of persistent or exertional symptoms

<table>
<thead>
<tr>
<th>Patient characteristics*</th>
<th>No persistent or exertional (n=3424)</th>
<th>Persistent symptoms (n=44)†</th>
<th>Exertional symptoms (n=137)‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>1101 (32)</td>
<td>16 (36)</td>
<td>70 (51)</td>
</tr>
<tr>
<td>Age, mean (SD)</td>
<td>20 (1)</td>
<td>20 (2)</td>
<td>20 (1)</td>
</tr>
<tr>
<td>BMI, mean (SD)</td>
<td>26 (5)</td>
<td>26 (6)</td>
<td>25 (5)</td>
</tr>
<tr>
<td>White-non-Hispanic</td>
<td>2191 (64)</td>
<td>27 (61)</td>
<td>83 (61)</td>
</tr>
<tr>
<td>Black</td>
<td>922 (27)</td>
<td>13 (30)</td>
<td>48 (35)</td>
</tr>
<tr>
<td>White-Hispanic</td>
<td>108 (3)</td>
<td>1 (2)</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>Mixed</td>
<td>72 (2)</td>
<td>0</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>Other§</td>
<td>87 (3)</td>
<td>2 (4)</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Pre-existing conditions*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sickle cell trait</td>
<td>37 (1)</td>
<td>0</td>
<td>3 (2)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>11 (0.3)</td>
<td>1 (2)</td>
<td>0</td>
</tr>
<tr>
<td>Hypertension</td>
<td>18 (0.6)</td>
<td>1 (2)</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>Asthma (mild-intermittent)</td>
<td>329 (10)</td>
<td>2 (4)</td>
<td>23 (17)‡</td>
</tr>
<tr>
<td>Asthma (mild-persistent or greater)</td>
<td>69 (2)</td>
<td>4 (9)‡</td>
<td>10 (7)‡</td>
</tr>
<tr>
<td>Immunosuppressive agent</td>
<td>6 (0.2)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Obesity (BMI &gt;30 kg/m²)</td>
<td>420 (12)</td>
<td>8 (18)</td>
<td>11 (8)</td>
</tr>
<tr>
<td>Initial symptoms in initially symptomatic patients¶</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>784 (39)</td>
<td>12 (32)</td>
<td>44 (41)</td>
</tr>
<tr>
<td>Loss of taste/smell</td>
<td>753 (38)</td>
<td>30 (79)†</td>
<td>42 (40)</td>
</tr>
<tr>
<td>Nasal congestion</td>
<td>631 (31)</td>
<td>11 (29)</td>
<td>20 (19)‡</td>
</tr>
<tr>
<td>Sore throat</td>
<td>629 (31)</td>
<td>7 (18)</td>
<td>27 (25)</td>
</tr>
<tr>
<td>Myalgias</td>
<td>563 (28)</td>
<td>8 (21)</td>
<td>26 (24)</td>
</tr>
<tr>
<td>Cough</td>
<td>554 (28)</td>
<td>11 (29)</td>
<td>39 (36)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>502 (25)</td>
<td>15 (39)</td>
<td>32 (30)</td>
</tr>
<tr>
<td>Fever</td>
<td>473 (24)</td>
<td>8 (21)</td>
<td>31 (29)</td>
</tr>
<tr>
<td>Chills</td>
<td>259 (13)</td>
<td>3 (8)</td>
<td>13 (12)</td>
</tr>
<tr>
<td>Shortness of breath</td>
<td>188 (9)</td>
<td>9 (24)†</td>
<td>30 (28)†</td>
</tr>
<tr>
<td>Rhinorrhea</td>
<td>170 (8)</td>
<td>3 (8)</td>
<td>3 (3)</td>
</tr>
<tr>
<td>Chest pain</td>
<td>99 (5)</td>
<td>6 (16)‡</td>
<td>19 (18)‡</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>91 (5)</td>
<td>3 (8)</td>
<td>8 (7)</td>
</tr>
<tr>
<td>Other</td>
<td>87 (4)</td>
<td>3 (8)</td>
<td>4 (4)</td>
</tr>
<tr>
<td>Nausea</td>
<td>77 (4)</td>
<td>2 (5)</td>
<td>6 (6)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>32 (2)</td>
<td>2 (5)</td>
<td>3 (3)</td>
</tr>
<tr>
<td>Exercise intolerance</td>
<td>6 (0.3)</td>
<td>0</td>
<td>1 (0.9)</td>
</tr>
<tr>
<td>Palpitations</td>
<td>4 (0.2)</td>
<td>0</td>
<td>1 (0.9)</td>
</tr>
<tr>
<td>COVID-19 toes/ fingers</td>
<td>2 (0.1)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Presented as n (%) unless noted otherwise.
*Partial data for available for the following characteristics: age n=3412 (no persistent or exertional symptoms), sex 1 patient responded as non-binary in the no persistent or exertional group, BMI n=3040 (no persistent or exertional symptoms), race n=3380 (no persistent or exertional symptoms/n=43 (persistent symptoms), pre-existing conditions n=3204 (no persistent or exertional symptoms/n=136 (exertional symptoms)).
†There were eight athletes who were included in both the persistent symptoms group and the exertional symptoms group.
‡P<0.05 compared with the reference group (no persistent or exertional symptoms).
§Other category includes Asian, American-Indian, Native Hawaiian, Pacific Islander and self-selected other.
¶The number of asymptomatic athletes during initial infection for each group was as follows: no persistent or exertional (n=1056), persistent symptoms (n=0), exertional symptoms (n=18). For the remaining patients, initial symptom type was available in the following: no persistent or exertional (n=2005), persistent symptoms (n=38), exertional symptoms (n=108), BMI, body mass index.

Figure 2  Duration of symptoms for athletes with persistent symptoms. *Denotes athletes with ongoing symptoms on last follow-up.
†Denotes athletes with exertional cardiopulmonary symptoms on return to exercise.

were present in 44/3529 (1.2%). The total symptom duration for each athlete with persistent symptoms is shown in figure 2. Of the athletes with persistent symptoms, 44 (1.2%) had symptoms >3 weeks, 28 (0.8%) had symptoms >4 weeks and 2 (0.06%) had symptoms >12 weeks. The type of persistent symptom(s) was reported in 40/44 (91%) athletes. The most common persistent symptom was loss of taste/smell (63%), followed by SOB (20%), cough (15%) and chest pain (15%) (figure 3A). Twenty-three (58%) athletes with known persistent symptom type had only isolated loss of taste/smell. There was no difference in the presence of initial moderate or cardiopulmonary symptoms in athletes with and without persistent symptoms (47% vs 52%, p=0.68). When excluding athletes whose only persistent symptom was isolated loss of taste/smell, there also was no difference in the presence of initial moderate or cardiopulmonary symptoms in athletes with and without persistent symptoms (69% vs 52%, p=0.28). Similarly, when comparing athletes with initial mild symptoms to those with initial moderate or cardiopulmonary symptoms, there was no significant difference in the development of persistent symptoms (2.0% vs 1.6%, p=0.68). No athlete with persistent symptoms had abnormal triad testing (ECG 0/43, troponin 0/43, TTE 0/44). An overview of the advanced diagnostic testing performed for athletes with isolated persistent symptoms is presented in online supplemental figure 1.
Eight of 44 (18%) athletes with persistent symptoms also had exertional cardiopulmonary symptoms on return to exercise, and diagnostic testing performed in these athletes are included in figure 4 (so each diagnostic test is counted only once). Of these eight athletes with both persistent and exertional symptoms, one athlete received a diagnosis of postural tachycardia syndrome (POTS), and one was diagnosed with pneumonia. No athletes with isolated persistent symptoms without exertional symptoms on return to exercise were diagnosed with SARS-CoV-2-associated sequelae.

Exertional cardiopulmonary symptoms cohort

The presence or absence of exertional symptoms on return to exercise was reported in 3393/3597 (94.3%) athletes. Exertional cardiopulmonary symptoms were present in 137/3393 (4.0%) athletes on return to exercise. Female and black athletes had a higher proportion of exertional cardiopulmonary symptoms compared with athletes without persistent or exertional symptoms (table 1). Of the athletes with exertional cardiopulmonary symptoms, the most common symptom was SOB (58%), followed by chest pain (36%), and exercise intolerance/fatigue (23%) (figure 3B). The median time from initial infection (symptom onset or positive SARS-CoV-2 test) to return to exercise was 17 days (IQR 13–21).

An overview of the advanced diagnostic testing performed for athletes with exertional symptoms is presented in figure 4. Further clinical evaluation and diagnostic testing led to the diagnosis of SARS-CoV-2-associated sequelae in 12/137 (8.8%) athletes with exertional symptoms (five cardiac involvement, two pneumonia, two inappropriate sinus tachycardia, two POTS and one pleural effusion) (figure 5, online supplemental figure 2). Triad testing was abnormal in 5 athletes with exertional
symptoms, including 1/132 (0.8%) athlete who underwent ECG testing (diffuse T-wave inversions) and 4/117 (3.4%) athletes who underwent a TTE (LVEF <50%, 1 small pericardial effusion, 1 large pleural effusion). Five of 44 (11.4%) athletes who underwent a CMR for exertional cardiopulmonary symptoms on return to exercise had probable or definite SARS-CoV-2 cardiac involvement, including 3 cases of pericardial involvement, 1 definite case of myopericardial involvement and 1 probable case of myopericardial involvement. One athlete with pneumonia and one athlete with POTS also had persistent symptoms.

The results of CMR testing for SARS-CoV-2 cardiac involvement in athletes with exertional cardiopulmonary symptoms on return to exercise are presented in online supplemental table 2. Of athletes with exertional chest pain who underwent CMR, a total of 5/24 (20.8%) had probable or definite cardiac involvement. For athletes with exertional cardiopulmonary symptoms other than chest pain who underwent CMR (n=20), there were no cases of probable or definite SARS-CoV-2 cardiac involvement. The median time from initial infection to CMR was 44 days (IQR 29–70).

**DISCUSSION**

We report the prevalence and clinical implications of persistent symptoms or exertional cardiopulmonary symptoms on return to exercise in collegiate athletes following SARS-CoV-2 infection, with the following key findings. First, both the prevalence of persistent symptoms from initial illness (1.2%) and exertional symptoms on return to exercise (4.0%) were low. Second, no diagnosis of SARS-CoV-2-associated sequelae was made following clinical evaluation or advanced diagnostic testing in athletes with only persistent symptoms. However, 8.8% of athletes with exertional cardiopulmonary symptoms on return to exercise had SARS-CoV-2-associated sequelae. Third, in athletes who had chest pain on return to exercise and underwent CMR (n=24), probable or definite SARS-CoV-2 cardiac involvement was found in 20.8% of cases.

The concern for potential cardiac inflammation and exercise-induced cardiac events in athletes with SARS-CoV-2 infection resulted in a variety of athlete ‘return-to-play’ screening guidelines. These guidelines have undergone several iterations based on evolving clinical experience and published evidence. The most recent recommendations suggest athletes suffering from asymptomatic or mild infections do not require cardiac testing due to a low incidence of SARS-CoV-2 cardiac involvement, a position further supported by the lack of adverse cardiac events in short-term clinical follow-up. While initial data from the ORCCA Registry found that athletes with cardiopulmonary symptoms, including chest pain and dyspnoea, were at increased risk of SARS-CoV-2 cardiac involvement (OR 3.1, 95% CI 1.2 to 7.8), the analysis did not distinguish between the presence of cardiopulmonary symptoms during the acute illness vs those present on return to exercise. Our current study specifically examined the clinical implications of exertional cardiopulmonary symptoms, finding that exertional chest pain on return to exercise presents a potentially high risk (20.8%) of probable or definite SARS-CoV-2 cardiac involvement. In this cohort, cardiac involvement included the pericardium in all cases, with myocardial involvement found in two athletes. Therefore, a comprehensive cardiac evaluation inclusive of CMR should be considered in athletes presenting with exertional chest pain on return to exercise.

Concern for the effects of postacute COVID-19 symptoms on athletic performance have been reported in several high-profile cases in the media. Additionally, the prevalences of prolonged symptoms in varying populations of non-athletes with non-severe COVID-19 illness have been reported in up to 47% of patients. Our results indicate that persistent symptoms following infection (1.2%) or exertional symptoms on return to exercise (4.0%) are relatively rare in a large cohort of collegiate athletes, and only 0.06% of athletes in this study fulfilled the contemporary definition of PACS (symptoms lasting >12 weeks) on last follow-up. The percentage of athletes with persistent symptoms other than isolated loss of taste/smell was also very low (0.6%). Thus, our findings support that the vast majority of athletes will not be limited by a prolonged illness course or symptoms on return to exercise. While the reasons for a low prevalence of PACS in collegiate athletes were not investigated in this study, we hypothesise that high fitness levels and an otherwise healthy cohort of young competitive athletes may have been protective against the development of persistent symptoms. In a study of 48 440 adult patients with COVID-19, higher levels of physical activity were associated with a lower risk of severe COVID-19 outcomes.

**Clinical implications**

Findings from this study highlight the importance of continual evaluation and follow-up in athletes returning to exercise following SARS-CoV-2 infection. The presence of exertional cardiopulmonary symptoms on return to exercise, in particular exertional chest pain, warrants clinical evaluation, even in athletes with initial negative cardiac testing after resolution of acute symptoms. As SARS-CoV-2 cardiac involvement is relatively infrequent in young competitive athletes (0.5%–3%) and adverse cardiac events are rare, this study provides further support for a symptom-guided cardiac evaluation, including symptoms that present as athletes return to exercise. A comprehensive evaluation, including consideration for CMR, is recommended in athletes with chest pain on return to exercise. A symptom-guided approach to cardiac testing after SARS-CoV-2 infection in athletes is reflected in current expert consensus recommendations. While this study suggests that exertional chest pain on return to exercise presents a higher risk for SARS-CoV-2 cardiac involvement, it is important not to discount other known clinical signs and symptoms of potential myocarditis.

**Limitations**

Several important limitations warrant discussion. First, there was no standardised diagnostic workup for athletes with persistent symptoms or exertional cardiopulmonary symptoms on return to exercise, and diagnostic testing was performed at the discretion of the participating institutions. While this represents ‘real-world’ management of young athletes with SARS-CoV-2 infection, new pathologic diagnoses may have been missed. Second, the higher proportion of exertional cardiopulmonary symptoms in female and black athletes remains of unclear significance and an important area of future work. Third, the results of diagnostic testing were obtained from unblinded clinical interpretation and may have resulted in a degree of observer bias. Unbiased imaging adjudication at a centralised core facility also represents an important area of future investigation. Finally, as athletes diagnosed with SARS-CoV-2 cardiac involvement after initial cardiac testing were restricted from sport prior to a return to exercise, further statistical comparisons regarding the yield of initial cardiac testing vs cardiac testing as a result of exertional symptoms was not possible.
What are the findings?

⇒ Among 3597 US collegiate athletes with SARS-CoV-2 infection, there was a low prevalence of persistent symptoms >3 weeks from initial illness (1.2%) and a low prevalence of exertional cardiopulmonary symptoms on return to exercise (4.0%).

⇒ No athlete with isolated persistent symptoms was diagnosed with SARS-CoV-2-associated clinical sequelae.

⇒ In athletes with exertional chest pain on return to exercise who underwent cardiac MRI (n=24), probable or definite SARS-CoV-2 cardiac involvement was found in 20.8% of cases.

How might it impact on clinical practice in the future?

⇒ Monitoring athletes for the presence of new cardiopulmonary symptoms as they resume exercise following SARS-CoV-2 infection is important to ensure a safe return to sport.

⇒ The presence of exertional cardiopulmonary symptoms on return to exercise, in particular exertional chest pain, warrants a thorough clinical evaluation, even in athletes with initial negative cardiac testing after SARS-CoV-2 infection.

⇒ Cardiac MRI should be considered in athletes with exertional chest pain after SARS-CoV-2 infection to investigate for cardiac sequelae.

Author affiliations

1Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA

2Cardiovascular Performance Program, Massachusetts General Hospital, Boston, Massachusetts, USA

3Department of Orthopedics and Rehabilitation, University of Wisconsin-Madison, Madison, Wisconsin, USA

4Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA

5Department of Family Medicine, Center for Sports Cardiology, University of Washington, Seattle, Washington, USA

Twitter Nathaniel Moulson @NateMoulson_MD, Stephanie A Kliethermes @stephkle2, Timothy W Churchill @TimChurchillMD, Kimberly G Harmon @DrKimHarmon and Jonathan A Drezner @Dreznertown

Acknowledgements The authors are grateful to all the collaborators at the participating institutions and to the Carson, Curran and Dolan families for supporting this work.

Collaborators ORRCA Investigators: Steering Committee: Irfan M. Asif, MD, Aaron L. Baggs, MD, James Borchers, MD, Jonathan A. Drezner, MD, Katherine M. Edenfield, MD, Michael S. Emery, MD, MS, Kyle Goehr, MD, Brian Hainline, MD, Kimberly G. Harmon, MD, Pei-Ni Jone, MD, Jonathan H. Kim, MD, MSC, Stephanie Kliethermes, PhD, William E. Kraus, MD, Rachel Lampert, MD, Matthew Leisbilder, MD, Benjamin D. Levine, MD, Matthew W. Martinez, MD, Nathaniel Moulson, MD, Francis G. O’Connor, MD, MPH, Manesh R. Patel, MD, Bradley J. Petek, MD, Dermot Phelan, MD, Lawrence D Rink, MD, Herman A Taylor, MD, MPH.Investigators: Carl Ade, PhD, Arman Alyan, MD, Jarrah Alalouf, MD, Chloé Amadicto, Scott Anderson, ATC, Stephanie Arlys-Mayor, MD, Jonathan S. Aubry, MD, Andrea Austin, MSN, RN, Brenden J. Balcik, MD, Timothy Beaver, MD, Nicolas Benitez, Brant Bertschresser, Thomas M. Best, MD, PhD, Tiffany Bohon, MD, Jonathan P. Bonnet, MD, MPH, Elizabeth Boiyington, James Bray, MD, Jenna Bryant, MD, Sean Carnahan, DO, Rachel Chamberlain, MD, Samantha Charters, ATC, Nicholas Chilli, MD, Daniel E. Clark, MD, Douglas Comeau, DO, Laura E Cook, MD, Deanna Corey, MD, Amy Costa, MD, Marshall Crowther, MD, Tarun Dalia, MD, Craig Davidson, MD, Katilin Davitt, MS, ATC, Annabelle De St. Maurice, MD, MPH, Peter N. Dean, MD, Jeffrey M. Dendy, MD, Katelyn DeZenzo, Courtney Dimitris, Jeanne Doperak, DO, Calvin Duffaut, MD, Craig Fafara, Katherine Fahy, MD, Jason Ferderber, MD, Megan Finn, Frank A. Fish, MD, R. Warne Fitch, MD, Angelo Galante, MD, Todd Gerlt, ATC, Amy Gest, MPA, Carla Gilson, ATC, Jeffrey Goldberger, MD, Joshua Goldman, MD, MBA, Erich Groeszinger, MD, Jonathan R. Guin, MD, Heather Halseth, Joshua Hare, MD, Beth Hartess, ATC, Nicolas Hatamiya, DO, Julie Haylett, RN, MSN, Neal Hazen, MBA, PT, ATC, LAT, Sean G. Hughes, MD, Yeun Hiroi, BS, Amy Hockenbrock, MD, Amanda Honsvall, MD, Jennifer Hopp, MD, Julia Howard, ATC, Samantha Huba, Mustafa Husaini, MD, Lindsay Huston, MD, Calvin Hwang, MD, Laura Irvin, DO, Val Gene Iven, MD, Robert Jones, MD, Donald Joyce, MD, Kristine Karlson, MD, Jeremy Kent, MD, Christian Klein, MD, Chris Klencz, MD, Michele Kirk, MD, Jordan Knight, Laura Knippa, MD, Madeleine Knutson, ATC, Louis E. Kovacs, MD, Yumi Kusche-A, Mary Lou Dussault, MD, Chris Lyndreath, Amy Leu, DO, Dylan Lothian, Maureen Lowery, MD, Andrew Lukjanczuk, MS, ATC, LAT, John M. MacKnight, MD, Lawrence M. Magee, MD, Marisa-Liisa Magnuson, DO, MS, Aaron V. Mares, MD, Anne Marquez, Grant McKinley, MD, Scott Meester, MD, Megan Meier, MD, Christopher Miles, MD, Emily Miller, MD, Hannah Miller, MD, SAE, ATC, LAT, Raul Mirrani, MD, Aaron J. Monroeau, MD, Benjamin Moorehead, MD, Robert J Myerburg, MD, Greg Myhyk, ATC, Andrew Navarre, DO, Aurellia Nattk, MD, Laika Nur, MD, Brooke E. Organ, MD, Meredith Pendergast, ATC, Frank A. Pettrone, MD, Jordan Pierce, ATC, Sourav K. Poddar, MD, Diana Priestman, Ian Quinn, DO, Fred Reifstreck, MD, Morgan Restivo, James B. Robinson, MD, Ryan Roe, PAC, Thomas Rosamond, MD, Carrie Rubertino Shearer, Diego Riveros, MD, Miguel Rueda, Takamasa Sakamoto, MD, MET, Brock Schnebel, MD, Anklt B. Shah, MD, MPH, Alan Shahataji, DO, Kevin Shannon, MD, Polly_Schoenfeld-Young, PA-C, Jonathan H. Soslows, MD, Sibbhan M. Statuta, MD, Mark Stovak, MD, Andrei Tarsici, Kenneth S. Taylor, MD, Kim Terrell, Matt Thomason, ATC, Jason Tso, MD, Daniel Vigil, MD, Francis Wang, MD, Jennifer Winningham, MS, ATC, LAT, Susan T. Zorn, MD.

Contributors All authors contributed to the study design, data collection, data analysis, manuscript writing and revision. JAD is the guarantor and responsible for the overall content.

Funding This study was funded in part by grants from the American Medical Society for Sports Medicine (AMSSM) Collaborative Research Network, the AMSSM Foundation, and the Ron Dolan Endowment Fund at the University of Washington. NM is also supported by the University of British Columbia Clinician Investigator Program.

Competing interests JAD is Editor-in-chief of BJSM and KGH is a Deputy Editor of BJSW. ALB has received funding from the National Institute of Health’s National Heart, Lung, and Blood Institute (NHLBI), the National Football League’s Association, and the American Heart Association and receives compensation for his role as team cardiologist from the US Olympic Committee / US Olympic Training Centers, US Soccer, US Rowing, the New England Patriots, the Boston Bruins, the New England Revolution, and Harvard University. KGH has stock options for $8 points for which she is also on the medical advisory board. MRP is on the Advisory Board for: Amgen, Bayer, Janssen, Heartflow, Medpace, and has research grant funding from NHLBI, Bayer, Janssen, Heartflow, Idorsia, and the Joel Cournette Foundation for research on athlete’s hearts.

Patient consent for publication Not applicable.

Ethics approval All aspects of this study were approved by the Massachusetts General Brigham Institutional Review Board (Protocol #2020P002667).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs Bradley J Petek http://orcid.org/0000-0002-6603-2262 Stephanie A Kliethermes http://orcid.org/0000-0001-9756-7406 Kimberly G Harmon http://orcid.org/0000-0002-3670-6609
REFERENCES